Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD phase III elecoglipron study in obesity or overweight with or without type 2 diabetes
ChiCTR2600135627Phase 3Not yet recruiting
- Sponsor
- Genertec Liaoyou Gem Flower Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elecoglipron in obesity, Overweight and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Genertec Liaoyou Gem Flower Hospital. Primary endpoint: Percentage change in body weight from baseline at Week 72. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
elecoglipron
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600135627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135627.